导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.70% | 1913/4773 |
| 近一周 | -1.09% | 2108/5467 |
| 近一月 | -2.39% | 928/5421 |
| 近一季 | -3.01% | 1342/5238 |
| 近半年 | -1.31% | 1898/4931 |
| 近一年 | 4.07% | 1755/4400 |
| 近两年 | 46.44% | 1595/2954 |
| 近三年 | 30.97% | 1038/2253 |
| 成立以来 | 86.40% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.05% 2085/4961 |
5.73% 2873/5312 |
- - |
- - |
| 2025 | 18.53% 2306/4813 |
-0.65% 2334/3635 |
4.01% 886/4076 |
11.91% 3116/4524 |
2.49% 933/4813 |
| 2024 | 15.17% 957/3463 |
2.75% 716/2808 |
-0.40% 759/3014 |
12.64% 2307/3129 |
-0.09% 1313/3463 |
| 2023 | -0.86% 476/2656 |
5.09% 831/2280 |
-0.29% 372/2385 |
- 401/2515 |
-5.40% 1344/2655 |
| 2022 | -11.74% 254/2207 |
-9.84% 355/1919 |
5.57% 873/2016 |
-9.22% 258/2113 |
2.14% 1029/2208 |
| 2021 | 3.30% 618/1822 |
-1.52% 509/1255 |
4.20% 912/1330 |
-0.85% 504/1466 |
1.53% 889/1822 |
| 2020 | 21.00% 697/1250 |
-8.49% 614/1028 |
8.22% 829/1067 |
12.38% 390/1164 |
8.71% 662/1184 |
| 2019 | 22.84% 640/1092 |
20.88% 606/754 |
-1.34% 306/804 |
-1.84% 679/850 |
4.93% 766/918 |
| 2018 | -19.11% 155/834 |
- - |
- - |
- - |
-10.71% 217/691 |
| 2017 | 11.85% 292/714 |
- - |
- - |
- - |
- - |
| 2016 | -9.91% 270/605 |
- - |
- - |
- - |
- - |
| 2015 | 8.17% 172/575 |
- - |
- - |
- - |
- - |
| 2014 | 54.03% 59/237 |
- - |
- - |
- - |
- - |
| 2013 | -5.26% 95/186 |
- - |
- - |
- - |
- - |
| 2012 | 5.70% 73/140 |
- - |
- - |
- - |
- - |
| 2011 | -20.11% 38/102 |
- - |
- - |
- - |
- - |
| 2010 | -14.37% 37/58 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 汇添富上证综合指数A VS. 长安沪深300非周期A(740101) |